Since identification of this oncogenic driver, efforts to develop new molecules to target KRAS have been ongoing; a molecule, denoted Oncrasin-1 shown in Fig. 1, being discovered in 2008 through a synthetic lethal screen with KRAS mutation in breast cancer cell lines (Guo et al. 2008). Here, KRAS is linked to breast cancer.